HOME >> BIOLOGY >> NEWS
Toward more effective paleolgenetic analysis

DNA preserved in bones undergoing fossilization deteriorates up to 50 times faster when stored in a museum than when the bones are buried in the ground. This has just been shown by a paleogenetics team led by Eva-Maria Geigl (Institut Jacques Mono / CNRS Paris). This study, which was published in the Proceedings of the US National Academy of Sciences 8 January 2007, shows that in order to improve the quality of paleogenetic analyses, archeological and paleontological remains should be treated like biological samples both during and after excavation. The findings show the need for a new methodology for the excavation, treatment and preservation of fossils. They also open up new prospects for paleogenetic research into freshly excavated fossils.

In paleogenetic research, it is essential to have well-preserved archeological material in order to obtain reliable results. At present, such research is only too rarely the result of close collaboration between the various disciplines involved: molecular biologists, archeologists, paleontologists and curators. Moreover, biologists mostly carry out such studies on samples stored in collections or in museums. However, there was no reason to suppose that the treatment carried out by fieldworkers (archeologists, paleontologists and curators), as well as storage conditions, were compatible with a paleogenetic approach. In fact, such analyses were often subject to a high failure rate, due partly to a lack of any ancient DNA detected by PCR , or to contamination by modern DNA.

An extensive study of around 250 fossil bones from 600 to 50 000 year old herbivores was carried out thanks to international cooperation between the Institut Jacques Monod at CNRS, the Museum of Natural Sciences in Madrid and a number of European, Turkish and Japanese paleontologists and archeologists. The work showed that mitochondrial DNA from freshly excavated, untreated fossil bones was amplified with a success rate of 46%. How
'"/>

Contact: Monica McCarthy
monica.mccarthy@cnrs-dir.fr
33-144-965-191
CNRS
17-Jan-2007


Page: 1 2 3

Related biology news :

1. Toward improved forms of a time-tested cholesterol-fighter
2. Dengue and other hemorrhagic fevers: Towards a first potential treatment
3. Towards predicting late-stage radiation toxicity
4. Toward a less expensive, more convenient treatment of Gauchers disease
5. Towards the mechanism of cell respiration
6. Towards a unified model of transcription termination
7. Towards a cheap and easy way to monitor HIV/AIDS
8. Towards targeted lung cancer treatment
9. Toward a better understanding of taste and smell impairments
10. Smokeless tobacco more effective than cigarettes for delivering dangerous carcinogens into the body
11. Developing a more effective vaccine for tuberculosis

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Toward more effective paleolgenetic analysis

(Date:2/13/2015)... , Feb. 13, 2015 ACT ... company that aims to transform cancer genomic information ... that the company has raised US$ 8 million in ... Based in Taipei, Taiwan , ... ACTDrug™, ACTOnco™. With the aim to implement next ...
(Date:2/9/2015)... RICHARDSON, Texas , Feb. 9, 2015  Lintec ... novel fabrication methods for carbon nanotube (CNT) macrostructures, including ... Texas at Dallas (UTD). Leveraging the vast ... Tokyo, Japan , Lintec of America ... Richardson, TX , focusing on scaling ...
(Date:2/5/2015)... 2015   Marvin Test Solutions , ... test solutions for military, aerospace, and manufacturing ... TS-323 GENASYS Test Platform to ... is a high-performance PXI-based system designed to ... require performance functional testing. GENASYS features a ...
Breaking Biology News(10 mins):ACT Genomics Raises $8 Million in its First Private Funding Round 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
(Date:2/28/2015)... 2015 Increasing its efforts to resolve the ... first three episodes of The GMO TRUTH podcast on both ... as it continues its mission to discover the truth and ... phase, to “uncover the truth about the GMOs in our ... GMO Truth Podcast is an expansion of the documentary/investigative film-making ...
(Date:2/27/2015)... Calif. , Feb. 27, 2015  Pharmacyclics, ... that longer-term toxicology studies for its newly developed ... or RA, have been completed. The results of ... U.S. Food and Drug Administration. The feedback received ... of the ongoing first-in-human study. Additional preclinical work ...
(Date:2/27/2015)... Halifax, Nova Scotia (PRWEB) February 27, 2015 ... clinical stage vaccine and immunotherapy company, today announced ... approved its application for Fast Track designation and ... DPX-Ebola vaccines, in conjunction with the mutual co-development ... had previously obtained Fast Track designation for the ...
(Date:2/27/2015)... , Feb. 27, 2015  Pfenex Inc. (NYSE ... development of biosimilar therapeutics, today announced that it will ... Marriott Marquis on March 2 nd at 3pm ... on a panel discussing the current state of the ... Biosimilars . For more information on ...
Breaking Biology Technology:The Walk a Mile Project Launches “GMO Truth” Podcast 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3
Cached News: